Stopping the Statin Before Bypass, or Betting on It to Prevent the Arrhythmia After
A 71-year-old man with a dilated left atrium and borderline kidneys is due for CABG tomorrow morning. His statin is either protecting him from the atrial fibrillation he's otherwise likely to develop after surgery, or setting up a myopathy his kidneys may not be equipped to clear.
Walter S., a 71-year-old man, has volunteered at his local food bank three mornings a week since retiring from four decades as a postal carrier, and was found to have severe three-vessel coronary disease on a stress test ordered after he mentioned feeling winded loading delivery boxes — discomfort he had been attributing to simple aging rather than to his heart. He has taken high-intensity atorvastatin for hyperlipidemia for the past six years, tolerated throughout, with a baseline CK in normal range and no myalgia in all that time, alongside longstanding but well-controlled hypertension that has left his kidneys at an eGFR of 48 — borderline, but stable across serial measurements over two years rather than drifting downward.
His echocardiogram, obtained as part of routine preoperative workup, shows a moderately dilated left atrium — a finding consistent with years of hypertensive remodeling rather than with any rhythm abnormality he has had so far, since he has remained in sinus rhythm throughout his cardiac workup. That combination, age plus atrial enlargement without prior atrial fibrillation, puts him at real elevated risk for new postoperative atrial fibrillation, a common and consequential complication of cardiac surgery. The trial usually reached for on that point does not actually describe him. ARMYDA-3 randomized two hundred statin-naive patients to atorvastatin 40mg daily beginning a week before surgery and found postoperative AF in 35% against 57% on placebo — a real effect, but the effect of starting a statin in someone who was not on one. Walter has six years of continuous high-intensity therapy already on board. Whether interrupting that for a single morning dose meaningfully erodes an anti-inflammatory effect six years in the building is a question ARMYDA-3 was never designed to answer, and it is the question actually in front of the team before his case.
The night before, deciding whether the statin comes with him to the OR
I want him continued on his statin straight through tomorrow morning. ARMYDA-3 found a real reduction in postoperative atrial fibrillation with perioperative statin therapy, and his dilated left atrium puts him at real elevated risk for exactly that complication. I don't want to interrupt a drug with a demonstrated protective signal for a risk that's mostly theoretical.
I'd hold it for at least twenty-four hours, and it's specifically because of his renal function, not a general anti-statin position. His eGFR is 48, and bypass itself carries a real risk of transient renal hypoperfusion — layering continued statin exposure on top of a kidney that may be about to get an acute stress isn't the same low-risk scenario as continuing it in a patient with normal renal reserve.
I'd also point out that ARMYDA-3 studied statin-naive patients starting therapy before surgery, not patients like him who've been on it for six years already. Whether one held dose meaningfully changes his POAF risk, given six years of established anti-inflammatory effect already on board, is a real question the trial doesn't actually answer.
That's a fair distinction I hadn't fully considered — you're right that ARMYDA-3's population was starting therapy, not interrupting years of established treatment, and I don't have direct evidence that a single held dose meaningfully erodes whatever protective effect six years of continuous therapy has already built up.
I'm comfortable holding tomorrow's dose given that reasoning, particularly given his renal function is genuinely borderline rather than a purely theoretical concern on my part. We'll resume it as soon as he's hemodynamically stable postoperatively rather than leaving it held indefinitely.
Agreed: statin held the morning of surgery given his borderline renal function, with resumption planned as soon as hemodynamically stable postoperatively rather than an extended interruption. Standard amiodarone POAF prophylaxis adopted as the primary protective strategy for the outcome the statin argument had originally centered on.
Not agreed as a general rule: whether the ARMYDA-3 statin-naive population genuinely generalizes to a decision about interrupting years of established therapy, a distinction the pharmacologist raised but that neither voice treated as fully settled by existing evidence. The surgeon's original POAF-prevention reasoning was not judged wrong, only reframed once the trial's actual population was named precisely.